FierceBiotech Jan 9, 2026 Roche returns to MediLink with promise of $570M near-term payments for another ADC
FierceBiotech Jan 9, 2026 Ollin eyes phase 3 after bispecific tops Vabysmo in early-stage trial, clearing more retinal disease faster
FierceBiotech Jan 8, 2026 Longtime Charles River leader Jim Foster to retire, with COO set to take the helm
FierceBiotech Jan 8, 2026 Lexeo Therapeutics, J&J team up to test heart pump technology for cardiac gene therapy delivery
FierceBiotech Jan 8, 2026 Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution
FierceBiotech Jan 8, 2026 Diagonal moves forward with $125M series B round, plots first-in-human study this year
FierceBiotech Jan 8, 2026 WEP Clinical grabs European CRO Siron Clinical, broadening global capabilities
FierceBiotech Jan 8, 2026 Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
FierceBiotech Jan 7, 2026 Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate
FierceBiotech Jan 7, 2026 Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus’ replication
FierceBiotech Jan 7, 2026 Staar Surgical's takeover saga ends as shareholder revolt stops Alcon’s attempted merger deal